Connective Tissue Growth Factor Is Required for Normal Follicle Development and Ovulation
Department of Pathology & Immunology, Baylor College of Medicine, Houston, Texas 77030, USA. Molecular Endocrinology
(Impact Factor: 4.02).
08/2011; 25(10):1740-59. DOI: 10.1210/me.2011-1045
Connective tissue growth factor (CTGF) is a cysteine-rich protein the synthesis and secretion of which are hypothesized to be selectively regulated by activins and other members of the TGF-β superfamily. To investigate the in vivo roles of CTGF in female reproduction, we generated Ctgf ovarian and uterine conditional knockout (cKO) mice. Ctgf cKO mice exhibit severe subfertility and multiple reproductive defects including disrupted follicle development, decreased ovulation rates, increased numbers of corpus luteum, and smaller but functionally normal uterine horns. Steroidogenesis is disrupted in the Ctgf cKO mice, leading to increased levels of serum progesterone. We show that disrupted follicle development is accompanied by a significant increase in granulosa cell apoptosis. Moreover, despite normal cumulus expansion, Ctgf cKO mice exhibit a significant decrease in oocytes ovulated, likely due to impaired ovulatory process. During analyses of mRNA expression, we discovered that Ctgf cKO granulosa cells show gene expression changes similar to our previously reported granulosa cell-specific knockouts of activin and Smad4, the common TGF-β family intracellular signaling protein. We also discovered a significant down-regulation of Adamts1, a progesterone-regulated gene that is critical for the remodeling of extracellular matrix surrounding granulosa cells of preovulatory follicles. These findings demonstrate that CTGF is a downstream mediator in TGF-β and progesterone signaling cascades and is necessary for normal follicle development and ovulation.
Available from: Yuval Yung
- "The different stages in follicle development are characterized by specific molecular markers and hormonal profiles which differentiate early antral from pre-ovulatory and luteinized follicles. The gene expression profile of the early antral follicle typically shows low levels of follicle stimulating hormone receptor (FSHR) (Abdennebi et al., 1999; Camp et al., 1991; O'Shaughnessy et al., 1996; Weil et al., 1999), luteinizing hormone/choriogonadotrophin receptor (LHCGR) (Abdennebi et al., 1999; Camp et al., 1991), cholesterol side-chain cleavage enzyme (CYP11A1) (Oonk et al., 1990), aromatase (CYP19A1), amphiregulin (AREG) and epiregulin (EREG), (Ashkenazi et al., 2005; Zamah et al., 2010), whereas progression to the pre-ovulatory follicle consequent upon an increase in FSH secretion, results in an increase in FSHR and LHCGR (Ashkenazi et al., 2005; Zamah et al., 2010) along with concomitant increases in CYP11A1 (Oonk et al., 1990) and CYP19A1 (Clement and Monniaux, 2012; Fitzpatrick et al., 1997; Kawai et al., 2012; Nagashima et al., 2011) expression in preparation for the LH surge (Camp et al., 1991; Hillier, 2001; Hsueh et al., 2000). Following luteinization, the genetic profile shifts to AREG and EREG translation promoting progesterone synthesis and secretion, resulting in ovulation (Zamah et al., 2010; Clement and Monniaux, 2012; Conti et al., 2006; Su et al., 2010). "
[Show abstract] [Hide abstract]
ABSTRACT: Cell culture techniques of human mural granulosa cells (MGCs) serve as a major in vitro tool. However, the use of luteinized MGCs has major limitations due to their luteinized state. Our aim was to establish a standardized protocol for the culture of MGCs as a model for different stages of folliculogenesis. We showed that early-non-luteinized, preovulatory-non-luteinized and luteal-MGCs have distinct gene expression pattern. After 4 days of incubation of luteinized-MGCs, ovulatory genes mRNA's achieve expression levels similar to the early non-luteinized follicles. FSH stimulation for 48 hours of these 4 days cultured MGCs showed ovulatory genes mRNA's expression similar to the pre-ovulatory- non-luteinized follicles. These FSH-stimulated cells responded to hCG stimulation in a pattern similar to the response of pre-ovulatory follicles. This novel model may provide a standardized research tool for delineation of the molecular processes occurring during the latter stages of follicular development in the human ovary.
Available from: Klaus-Peter Brüssow
- "Recent studies have shown that the morphological and genetic transition from the primordial follicle stage through to ovulation and corpus luteum formation is associated with the activation of a growth factor signalling cascade that highly regulates the proliferation and differentiation of ovarian cells (Figure 1), (Nagashima et al. 2011; Joseph et al. 2012; Kawano et al. 2012). The most important growth factors include genes of the TGFB superfamily that are expressed in mammalian ovarian somatic cells and in oocytes in a stagespecific manner, and thereby, function as intraovarian regulators of folliculogenesis (Paradis et al. 2009; Nagashima et al. 2011; Corduk et al. 2012). The most important TGFB superfamily genes include bone morphogenic proteins 2, 4, 5, 6, 7, and 15 (BMP2, BMP4, BMP5, BMP6, BMP7, and BMP15) and growth differentiation factor 9 (GDF9), which are expressed throughout folliculogenesis and regulate key steps of follicle growth and development (Figure 2), (Knight and Glister 2006). "
[Show abstract] [Hide abstract]
ABSTRACT: The normal differentiation of follicles from the preantral to the antral stage is regulated by the synthesis and secretion of several important growth factors. Moreover, the proper growth and development of the oocyte and its surrounding somatic granulosa-cumulus cells is accomplished through the activation of paracrine pathways that form a specific cross-talk between the gamete and somatic cells. It has been shown that several growth factors produced by the ovary are responsible for the proper growth and development of follicles. The developmental competence of mammalian oocytes (also termed developmental potency) is defined as the ability of female gametes to reach maturation (the MII stage) and achieve successful monospermic fertilisation. Proper oocyte development during folliculo- and oogenesis also plays a critical role in normal zygote and blastocyst formation, as well as implantation and the birth of healthy offspring. Several molecular markers have been used to determine the developmental potency both of oocytes and follicles. The most important markers include transforming growth factor beta superfamily genes (TGFB), and the genes in this family have been found to play a crucial role in oocyte differentiation during oogenesis and folliculogenesis. In the present review, we summarise several molecular aspects concerning the assessment of mammalian oocyte developmental competence. In addition, we present the molecular mechanisms which activate important growth factors within the TGFB superfamily that have been shown to regulate not only follicle development but also oocyte maturation.
Available from: Lester F Lau
[Show abstract] [Hide abstract]
ABSTRACT: Members of the CCN family of matricellular proteins are crucial for embryonic development and have important roles in inflammation, wound healing and injury repair in adulthood. Deregulation of CCN protein expression or activities contributes to the pathobiology of various diseases - many of which may arise when inflammation or tissue injury becomes chronic - including fibrosis, atherosclerosis, arthritis and cancer, as well as diabetic nephropathy and retinopathy. Emerging studies indicate that targeting CCN protein expression or signalling pathways holds promise in the development of diagnostics and therapeutics for such diseases. This Review summarizes the biology of CCN proteins, their roles in various pathologies and their potential as therapeutic targets.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.